First‑Line Systemic Therapy for Pemphigus

Initial Treatment Regimen

• Initiate oral prednisolone at 1 mg/kg/day together with an adjuvant immunosuppressant (azathioprine, mycophenolate mofetil, or rituximab) as the first‑line approach for pemphigus vulgaris or foliaceus【1】.

Corticosteroid Dosing Strategies

• Standard dose: start prednisolone 1 mg/kg/day for most patients【1】 (consensus).
• Milder disease: a starting dose of 0.5–1 mg/kg/day provides comparable long‑term efficacy【1】 (consensus).
• Non‑response: if no clinical improvement within 5–7 days, increase the dose by 50–100 % until new blister formation ceases and existing lesions begin to heal【1】 (expert recommendation).
• Severe disease: begin with pulsed intravenous corticosteroids (methylprednisolone 500–1000 mg or dexamethasone 100 mg for three consecutive days) followed by oral prednisolone 1 mg/kg/day【1】 (expert recommendation).
• Safety note: up to 77 % of pemphigus‑related deaths are attributable to corticosteroid toxicity, underscoring the need for steroid‑sparing strategies【1】 (observational data).
• RCT evidence: a randomized trial comparing low‑dose (30–60 mg/day) versus high‑dose (120–180 mg/day) prednisolone showed no difference in time to disease control, 5‑year relapse rates, or mortality【1】 (high‑quality evidence).

Mandatory Adjuvant Immunosuppressants

• Add one of the following from treatment initiation:
  
  • Azathioprine 2–3 mg/kg/day after confirming normal TPMT activity【1】 (expert recommendation).
  • Mycophenolate mofetil 2–3 g/day【1】 (expert recommendation).
  • Rituximab using the rheumatoid‑arthritis protocol (two 1‑g infusions 2 weeks apart)【1】 (expert recommendation).
• Adjuvant agents are primarily for remission maintenance because of their delayed onset of action【1】 (expert opinion).

Response Assessment and Tapering

• Initial disease control is defined as the absence of new lesions together with the onset of healing in pre‑existing lesions【1】 (clinical definition).
• Begin corticosteroid taper only after remission (no new blisters and healing of the majority of skin and mucosal lesions)【1】.
• Target taper to ≤10 mg prednisolone daily【1】 (expert recommendation).

Osteoporosis Prophylaxis

• Perform immediate osteoporosis risk assessment when systemic corticosteroids are started and commence calcium + vitamin D supplementation as a non‑negotiable safety measure【1】 (expert recommendation).

Second‑Line Therapy & Treatment Failure

• Switch to an alternative corticosteroid‑sparing agent if treatment failure occurs with the first‑line adjuvant【1】. Failure is defined as:
  
  • Persistent disease activity despite prednisolone 1.5 mg/kg/day for ≥3 weeks, or
  • Lack of healing after 12 weeks of any of the following:
    
    • Azathioprine 2.5 mg/kg/day (normal TPMT)【1】
    • Mycophenolate mofetil 1.5 g twice daily【1】
    • Cyclophosphamide 2 mg/kg/day【1】
    • Methotrexate 20 mg/week【1】
• If gastrointestinal intolerance develops with mycophenolate mofetil, substitute mycophenolic acid 720–1080 mg twice daily【1】 (expert recommendation).

Third‑Line/Refractory Options

• For disease refractory to first‑ and second‑line agents, consider:
  
  • Cyclophosphamide (oral or pulsed IV)【1】【2】
  • Intravenous immunoglobulin (IVIG)【1】
  • Immunoadsorption【1】
  • Methotrexate【1】
  • Plasmapheresis / plasma exchange【1】

Pulsed Intravenous Cyclophosphamide (DCP) Protocol

• This regimen achieved 81 % remission off all therapy for ≥2 years in the original series【2】 (observational cohort).
• Adverse events: amenorrhea in 20–85 % of menstruating women; hemorrhagic cystitis in 6 %【2】 (observational data).
• An alternative dosing strategy—IV cyclophosphamide 1.5 mg/kg monthly (max 1500 mg) with mesna—is used to lower cystitis risk【2】 (expert recommendation).

Safety Monitoring

• Screen for pituitary‑adrenal suppression in patients receiving the DCP regimen; it occurs in ≈55 % of cases【2】 (observational data).

Clinical Pitfalls (What to Avoid)

• Monotherapy with corticosteroids is discouraged; mandatory adjuvant immunosuppression from the start reduces cumulative steroid exposure and steroid‑related mortality【1】.
• Premature tapering before complete remission increases relapse risk; taper only after remission is achieved【1】.
• Delaying a switch when treatment‑failure criteria are met leads to prolonged ineffective therapy; promptly change to an alternative adjuvant【1】.
• Neglecting osteoporosis prophylaxis; calcium and vitamin D supplementation must begin immediately with systemic steroids【1】.

Guideline Recommendations for Oral Pemphigus Management

First‑Line Systemic Therapy

• Initiate oral prednisolone at 1 mg/kg/day for most patients with oral pemphigus vulgaris; this dose provides rapid disease control and is supported by high‑quality evidence (RCT) [3][4].
• For milder, oral‑only disease, a lower starting dose of 0.5–1 mg/kg/day may be used, with similar efficacy [3][5].
• If no clinical response is observed within 5–7 days, increase the prednisolone dose by 50–100 % increments until disease control is achieved 5.
• Expected timeline of improvement: cessation of new lesions in 2–3 weeks and complete mucosal healing in 3–8 weeks [4][6].
• Combination therapy (prednisolone + rituximab) yields markedly higher remission: 89 % achieve complete remission off all treatment at 2 years versus 28 % with prednisolone alone (Level I RCT) [4][6].
• Recommended simultaneous adjuvant agents (choose one):
  
  • Azathioprine 2–3 mg/kg/day (after TPMT testing) [3][4]
  • Mycophenolate mofetil 2–3 g/day [3][4]
  • Rituximab – two 1 g infusions, 2 weeks apart (RA protocol) [3][4]
• Adjuvant drugs are crucial for remission maintenance; early initiation reduces the need for prolonged high‑dose steroids and lowers steroid‑related mortality (up to 77 % of pemphigus deaths) [3][4]5.

Topical Adjunctive Therapy

• Betamethasone sodium phosphate 0.5 mg dissolved in 10 mL water, used as a 2–3 min rinse‑and‑spit 1–4 times daily 7.
• Fluticasone propionate diluted similarly, administered twice daily 7.
• Clobetasol 0.05 % mixed with 50 % Orabase, applied twice weekly to localized dried mucosal lesions 7.
• Tacrolimus 0.1 % ointment twice daily provides efficacy comparable to triamcinolone 0.1 % paste in a split‑mouth trial 7.

Corticosteroid Tapering Strategy

• After achieving remission (no new blisters and healing of the majority of lesions), gradually taper prednisolone with the goal of reaching ≤10 mg daily [3][4].
• Premature discontinuation is associated with a 47 % relapse rate when therapy is stopped after only 1 year [4][6].

Second‑Line and Third‑Line Options

• Treatment failure is defined as persistent disease despite:
  
  • Prednisolone 1.5 mg/kg/day for ≥ 3 weeks, or
  • Azathioprine 2.5 mg/kg/day (normal TPMT) for ≥ 12 weeks, or
  • Mycophenolate mofetil 1.5 g twice daily for ≥ 12 weeks, or
  • Cyclophosphamide 2 mg/kg/day, or
  • Methotrexate 20 mg/week [3][4]5.
• Second‑line: switch to an alternative corticosteroid‑sparing agent (azathioprine, mycophenolate mofetil, or rituximab) [3][4]5.
• If gastrointestinal intolerance occurs with mycophenolate mofetil, use mycophenolic acid 720–1080 mg twice daily [3][4].
• Third‑line (for refractory disease) may include:
  
  • Cyclophosphamide 7
  • Intravenous immunoglobulin 5
  • Immunoadsorption 5
  • Methotrexate 5
  • Plasmapheresis or plasma exchange 5.

Safety and Monitoring

• Assess osteoporosis risk immediately upon initiating systemic corticosteroids and implement prophylaxis as indicated [3][4].
• Maintain high‑quality oral hygiene; painful erosions impede brushing, leading to plaque accumulation and exacerbating inflammation 7.
• Patients with pemphigus vulgaris exhibit worse periodontal status compared with matched controls 7.

Long‑Term Outcomes

• Complete remission off therapy is achieved in 38 % of patients at 3 years, 50 % at 5 years, and 75 % at 10 years [4][6].

Dietician Involvement and Nutritional Management in Pemphigus Vulgaris

Indications for Dietician Referral

• Formal dietician consultation is recommended when oral intake becomes impaired by painful mucosal or skin lesions, because nutritional compromise can delay healing and worsen clinical outcomes. The British Association of Dermatologists includes dietician involvement as an essential component of comprehensive PV care when oral intake is compromised. 8

Corticosteroid‑Related Dietary Management

• Patients receiving systemic corticosteroids should be screened for steroid‑induced hyperglycaemia and, if present, receive tailored dietary modifications to control blood glucose levels. 9
• Immediate calcium and vitamin D supplementation should be instituted as part of osteoporosis prophylaxis when high‑dose corticosteroids are started. 9

Therapeutic Regimen and Healing Timeline

• First‑line therapy for PV consists of oral prednisolone at approximately 1 mg/kg/day together with an adjuvant immunosuppressant (e.g., azathioprine, mycophenolate mofetil, or rituximab). 9
• Healing of oral erosions typically requires 3–8 weeks even under optimal immunosuppressive treatment, making sustained nutritional support crucial during this period. 9